Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Facial skin aging is a complex process combining factors such as sun exposure, smoking and
those that are believed to be inherited. Changes in the skin over time including decreased
thickness result in skin atrophy, wrinkling, sagging, yellowness and changes in pigmentation.
Redermic is a cosmetic cream that has been evaluated clinically but not in comparison to
tretinoin nor in combination with tretinoin. There is no data on the safety and efficacy of
Redermic as compared to topical tretinoin.
Rejuva is a cream currently approved by Health Canada for the treatment of photodamaged skin.
It contains 0.025% tretinoin one of the most widely studied topical product for skin aging.
Studies have shown that topical tretinoin increases collagen synthesis and epidermal
thickness thereby improving the appearance of skin aging. The efficacy of Rejuva combined
with another topical cosmetic cream such as Redermic in the treatment of skin aging is
unknown.
One hundred and twenty (120) subjects with signs of skin aging participated in this
single-blind study to evaluate the efficacy and tolerance of Redermic versus Rejuva-A™
(0.025% tretinoin) and Redermic in combination with Rejuva-A™ (0.025% tretinoin).